title: Possibility of alveolar bone promoting enhancement by using lipophilic and/or hydrophilic zinc related compounds in zinc-deficient osteoporosis rats.
abstract: The purpose of this research is improvement of therapeutic treatment for periodontitis by using lipophilic and/or hydrophilic zinc materials. The sample suspension injections were prepared from zinc octanate (C8Zn), zinc stearate (C18Zn), zinc sulfate hepta-hydrate (ZnSO4) and tricalcium phosphate (ZnTCP) containing 6.17 w/w% zinc. After administrating of all injections to around alveolar bone of zinc-deficient osteoporosis rats, plasma Zn concentration, bone mineral content (BMC) of jawbone, BMC and bone mechanical strength (BMS) of femur and permeability tests for hairless rat stripped skin were measured as therapeutic scores. BMC and BMS were measured by using an X-ray computing tomography and the three-point bending method, respectively. The body weight, plasma Zn concentrations and the area under curve (AUC) for Zn of C8Zn, C18Zn and ZnTCP group rats were higher than those of control group, but those of ZnSO4 group were not changed. BMC of alveolar bone and femur and BMS of femur for C8Zn and C18Zn groups for 12 weeks were significantly higher than those of the control group, but those of ZnSO4 group were not changed. Stripped rat skin permeability treated by the hydrophilic creams containing C8Zn was 5-times higher than that of ZnTCP.
authors.affiliation: Research Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Tokudome
authors.forename: Makoto
authors.initials: M
authors.lastname: Otsuka
mesh_terms: D000818:Animals; D019540:Area Under Curve; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D003677:Deficiency Diseases / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005269:Femur / Q000378:metabolism; D057927:Hydrophobic and Hydrophilic Interactions; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism; D010518:Periodontitis / Q000188:drug therapy / Q000378:metabolism*; D051381:Rats; D054772:Rats, Hairless; D017207:Rats, Sprague-Dawley; D012867:Skin; D012869:Skin Absorption; D014131:Trace Elements / Q000097:blood / Q000172:deficiency / Q000627:therapeutic use*; D015032:Zinc / Q000097:blood / Q000172:deficiency / Q000627:therapeutic use*; D017967:Zinc Compounds / Q000097:blood / Q000627:therapeutic use*
chemical_list: D014131:Trace Elements; D017967:Zinc Compounds; D015032:Zinc